This article is more than 5 years old. Information may no longer be current.

Refractec reports ‘surge in sales’ for second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Refractec reported a gross revenue increase of 64% during the second quarter of 2004, according to a press release. Gross revenue reached $7.9 million compared with $4.8 million in the year-ago period, the company stated. Refractec attributed the unprecedented growth to the number of NearVision CK procedures performed during the quarter. The ViewPoint CK System is the only Food and Drug Administration-approved vision technology for the treatment of presbyopia. Conductive keratoplasty was initially approved for use in the U.S. in 2002 for the treatment of hyperopia.

During the quarter, there were 12,778 procedures performed with the system, according to the release. The company also sold 97 systems, representing an increase in system sales of 35% from the previous year’s quarter.